MISSISSAUGA, ON, Aug. 1, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the second quarter of 2024 after the market close on Thursday, August 8, 2024. The Company will also hold a conference call on Friday, August 9, 2024 at 8:30AM ET to discuss the results and corporate developments.
CONFERENCE CALL DETAILS
DATE: | August 9, 2024 |
TIME: | 8:30AM |
DIAL-IN NUMBER: | (+1) 437-900-0527 or 888-510-2154 |
REPLAY: | (+1) 289-819-1450 or 888-660-6345 Code: 28622# |
Expires: August 16, 2024 | |
WEBCAST: |
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.
| Last Trade: | C$14.45 |
| Daily Change: | 0.03 0.21 |
| Daily Volume: | 13,208 |
| Market Cap: | C$366.890M |
August 07, 2025 May 08, 2025 April 29, 2025 November 07, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
